NANOTECHNOLOGIES OPPORTUNITIES AND RISKS Présenté par KHAN Imran Entretien à l’institut romand de santé au travail Le ...
INTRODUCTION <ul><li>Richard Feynman, Nobel physic price 1965 </li></ul><ul><li>In 1974 with Norio Tanigushi </li></ul><u...
INTRODUCTION Domains and applications <ul><li>FOOD REVOLUTION </li></ul><ul><li>AGRICULTURE </li></ul><ul><li>SPACE CONQUE...
INTRODUCTION Domains and applications <ul><li>FOOD REVOLUTION </li></ul><ul><li>New food systems </li></ul><ul><li>Taste i...
INTRODUCTION Domains and applications <ul><li>AGRICULTURE </li></ul><ul><li>Monitoring system of lands </li></ul><ul><li>«...
INTRODUCTION Domains and applications <ul><li>SPACE CONQUEST </li></ul><ul><li>NASA </li></ul><ul><li>Space ships and orbi...
INTRODUCTION Domains and applications <ul><li>ENERGY </li></ul><ul><li>Artificial photosynthesis </li></ul><ul><li>Safer h...
INTRODUCTION Domains and applications <ul><li>ELECTRONIC INDUSTRIES </li></ul><ul><li>Databases capacity </li></ul><ul><li...
INTRODUCTION Domains and applications <ul><li>PHARMACEUTICAL INDUSTRIES </li></ul><ul><li>Targeting of precise places </li...
INTRODUCTION Domains and applications <ul><li>PHARMACEUTICAL INDUSTRIES </li></ul><ul><li>Cancer targeting </li></ul><ul><...
INTRODUCTION Domains and applications <ul><li>PHARMACEUTICAL INDUSTRIES </li></ul><ul><li>Nanodrugs </li></ul><ul><li>Spat...
INTRODUCTION Domains and applications <ul><li>PHARMACEUTICAL INDUSTRIES </li></ul><ul><li>Nanodrugs </li></ul>
INTRODUCTION Domains and applications <ul><li>PHARMACEUTICAL INDUSTRIES </li></ul><ul><li>« Lab-on-chip » </li></ul><ul><l...
INTRODUCTION Domains and applications <ul><li>Environmental safety </li></ul><ul><li>Decontamination potential </li></ul><...
INTRODUCTION Domains and applications <ul><li>To a new industrial era </li></ul><ul><li>« The 3rd revolution » </li></ul><...
NANOTECHNOLOGY RISKS <ul><li>In human and public health  </li></ul><ul><li>For the environment </li></ul><ul><li>For profe...
NANOTECHNOLOGY RISKS <ul><li>In human and public health  </li></ul><ul><li>Nanoparticles toxicity </li></ul><ul><li>Contac...
NANOTECHNOLOGY RISKS <ul><li>In human and public health  </li></ul><ul><li>4 risks factors for nanoparticles </li></ul><ul...
NANOTECHNOLOGY RISKS <ul><li>In human and public health  </li></ul><ul><li>4 risks factors for nanoparticles </li></ul><ul...
NANOTECHNOLOGY RISKS <ul><li>In human and public health  </li></ul><ul><li>4 risks factors for nanoparticles </li></ul><ul...
NANOTECHNOLOGY RISKS <ul><li>In human and public health  </li></ul><ul><li>4 risks factors for nanoparticles </li></ul><ul...
NANOTECHNOLOGY RISKS <ul><li>In human and public health  </li></ul><ul><li>Pathogen effects on the lungs </li></ul><ul><li...
NANOTECHNOLOGY RISKS <ul><li>For the environment </li></ul><ul><li>Difficulties for measurement and control </li></ul><ul>...
NANOTECHNOLOGY RISKS <ul><li>For professionals </li></ul><ul><li>Scientifics </li></ul><ul><li>Laboratories </li></ul><ul>...
RISK MANAGEMENT <ul><li>At european level, one example : NANOSAFE 1 </li></ul><ul><li>Control of productions </li></ul><ul...
RISK MANAGEMENT <ul><li>At european level, NANOSAFE 2 </li></ul>
RISK MANAGEMENT <ul><li>At european level, NANOSAFE 1 </li></ul><ul><li>Control of productions </li></ul><ul><li>Safe use ...
RISK MANAGEMENT <ul><li>At european level, NANOSAFE 2 </li></ul>SP1 : Detection and characterization techniques
RISK MANAGEMENT <ul><li>At european level, NANOSAFE 2 </li></ul>SP2 : Health hazard assessment
RISK MANAGEMENT <ul><li>At european level, NANOSAFE 2 </li></ul>SP3 : Development of secure industrial production systems ...
RISK MANAGEMENT <ul><li>At european level, NANOSAFE 2 </li></ul>SP4 : Societal and Environmental aspects
RISK MANAGEMENT <ul><li>At european level, NANOSAFE 2 </li></ul>
RISK MANAGEMENT <ul><li>Precautionary Principle </li></ul><ul><li>List nanoparticles </li></ul><ul><li>Produce new knowled...
CONCLUSIONS <ul><li>1 nanometer = 10 atoms </li></ul><ul><li>Exponential evolution </li></ul><ul><li>1188 « Nanoproducts...
CONCLUSIONS <ul><li>Nanoproducts already for consumers !!! </li></ul>Thanks for your attention !!!
of 35

Nanotechnologies et veille santaire finale

NANOTECHNOLOGIES ET VEILLE SANTAIRE FINALE
Published on: Mar 3, 2016
Published in: Technology      Business      
Source: www.slideshare.net


Transcripts - Nanotechnologies et veille santaire finale

  • 1. NANOTECHNOLOGIES OPPORTUNITIES AND RISKS Présenté par KHAN Imran Entretien à l’institut romand de santé au travail Le 8 Juillet 2011
  • 2. INTRODUCTION <ul><li>Richard Feynman, Nobel physic price 1965 </li></ul><ul><li>In 1974 with Norio Tanigushi </li></ul><ul><li>«  Nano-technology mainly consists of the processing of separation, consolidation, and deformation of materials by one atom or one molecule. » </li></ul><ul><li>In 80’s with K. Éric Drexler </li></ul><ul><li>« A strategical promising sector » </li></ul><ul><li>1nm to 100nm </li></ul><ul><li>Various applications </li></ul>
  • 3. INTRODUCTION Domains and applications <ul><li>FOOD REVOLUTION </li></ul><ul><li>AGRICULTURE </li></ul><ul><li>SPACE CONQUEST </li></ul><ul><li>MILITARY </li></ul><ul><li>ENERGY </li></ul><ul><li>CAR INDUSTRIES </li></ul><ul><li>ELECTRONICS INDUSTRIES </li></ul><ul><li>CHEMICALS INDUSTRIES </li></ul><ul><li>PHARMACEUTICAL INDUSTRIES </li></ul><ul><li>ENVIRONMENTAL SAFETY </li></ul>
  • 4. INTRODUCTION Domains and applications <ul><li>FOOD REVOLUTION </li></ul><ul><li>New food systems </li></ul><ul><li>Taste interactions </li></ul><ul><li>Healthcare specific delivery </li></ul><ul><li>Remedy for deficiencies, allergies,… </li></ul><ul><li>« Intelligent filters » </li></ul>
  • 5. INTRODUCTION Domains and applications <ul><li>AGRICULTURE </li></ul><ul><li>Monitoring system of lands </li></ul><ul><li>« Nanosensors » </li></ul><ul><li>Climat, water supply, diseases, parasites … </li></ul><ul><li>« Nanocatalysors » </li></ul><ul><li>Recycling agricultural wastes </li></ul>Vegetal oil Biodegradables fuels or dissolvants Biopolymers
  • 6. INTRODUCTION Domains and applications <ul><li>SPACE CONQUEST </li></ul><ul><li>NASA </li></ul><ul><li>Space ships and orbital stations </li></ul><ul><li>« Terraforming » planet Mars </li></ul><ul><li>« Space lift » </li></ul><ul><li>MILITARY </li></ul><ul><li>Lighter and more resistant materials </li></ul><ul><li>Miniaturized systems </li></ul>
  • 7. INTRODUCTION Domains and applications <ul><li>ENERGY </li></ul><ul><li>Artificial photosynthesis </li></ul><ul><li>Safer hydrogen container </li></ul><ul><li>CAR INDUSTRIES </li></ul>
  • 8. INTRODUCTION Domains and applications <ul><li>ELECTRONIC INDUSTRIES </li></ul><ul><li>Databases capacity </li></ul><ul><li>Information and communication </li></ul><ul><li>CHEMICAL INDUSTRIES </li></ul><ul><li>Specific catalysors </li></ul><ul><li>« Smart » magnetic fluids </li></ul><ul><li>Extreme cutting tools </li></ul>Treatment more efficient and speed
  • 9. INTRODUCTION Domains and applications <ul><li>PHARMACEUTICAL INDUSTRIES </li></ul><ul><li>Targeting of precise places </li></ul><ul><li>Biocompatible materials </li></ul><ul><li>Autodiagnosis kits </li></ul><ul><li>Improvement of surgical operations </li></ul><ul><li>Cancer targeting </li></ul><ul><li>Nanodrugs </li></ul><ul><li>« Lab-on-chip » </li></ul>
  • 10. INTRODUCTION Domains and applications <ul><li>PHARMACEUTICAL INDUSTRIES </li></ul><ul><li>Cancer targeting </li></ul><ul><li>« nanohorns » capsules </li></ul><ul><li>Cisplatine insertion </li></ul><ul><li>Liberation in the cell environment </li></ul><ul><li>Possible vectors for anti-tumor </li></ul><ul><li>Drug specific delivery system </li></ul>Cytotoxic action
  • 11. INTRODUCTION Domains and applications <ul><li>PHARMACEUTICAL INDUSTRIES </li></ul><ul><li>Nanodrugs </li></ul><ul><li>Spatiotemporal distribution </li></ul><ul><li>« Drug vectorization » </li></ul><ul><li>« Specific activation » </li></ul><ul><li>« Nano-manufacturing » </li></ul>Miniaturization project
  • 12. INTRODUCTION Domains and applications <ul><li>PHARMACEUTICAL INDUSTRIES </li></ul><ul><li>Nanodrugs </li></ul>
  • 13. INTRODUCTION Domains and applications <ul><li>PHARMACEUTICAL INDUSTRIES </li></ul><ul><li>« Lab-on-chip » </li></ul><ul><li>Reduce size of an actual laboratory </li></ul><ul><li>Evaluate rate of sugar, cholesterol </li></ul><ul><li>Recognize DNA sequences </li></ul><ul><li>Just with one blood droplet !!! </li></ul>D ivision into more little droplets Progressing in canals Specific reaction chambers
  • 14. INTRODUCTION Domains and applications <ul><li>Environmental safety </li></ul><ul><li>Decontamination potential </li></ul><ul><li>« nanofiltration » </li></ul><ul><li>Toxic metals </li></ul><ul><li>Bacteria </li></ul><ul><li>Virus </li></ul><ul><li>Major concern in water treatment </li></ul>
  • 15. INTRODUCTION Domains and applications <ul><li>To a new industrial era </li></ul><ul><li>« The 3rd revolution » </li></ul><ul><li>New functionnal properties </li></ul><ul><li>Numerous applications </li></ul><ul><li>2000 billions of dollars for 2015 </li></ul><ul><li>BUT </li></ul><ul><li>Health and environmental impacts not well know </li></ul>
  • 16. NANOTECHNOLOGY RISKS <ul><li>In human and public health  </li></ul><ul><li>For the environment </li></ul><ul><li>For professionals </li></ul>
  • 17. NANOTECHNOLOGY RISKS <ul><li>In human and public health  </li></ul><ul><li>Nanoparticles toxicity </li></ul><ul><li>Contact and penetration </li></ul><ul><li>Few clear informations </li></ul>Tiny and highly mobile Lungs Skin Blood stream Organs Cells Intestinal tracts
  • 18. NANOTECHNOLOGY RISKS <ul><li>In human and public health  </li></ul><ul><li>4 risks factors for nanoparticles </li></ul><ul><li>Size </li></ul><ul><li>Fix the rules of penetration </li></ul><ul><li>Migration into cytoplasm and the nucleus </li></ul><ul><li>Way through membranes </li></ul>
  • 19. NANOTECHNOLOGY RISKS <ul><li>In human and public health  </li></ul><ul><li>4 risks factors for nanoparticles </li></ul><ul><li>Surface </li></ul><ul><li>More atoms on particles </li></ul><ul><li>Increase of reactivity </li></ul><ul><li>Different properties </li></ul><ul><li>Adsorption and agglunitation </li></ul>Intrinsic chemistry Extrinsic chemistry Pathogenic agents
  • 20. NANOTECHNOLOGY RISKS <ul><li>In human and public health  </li></ul><ul><li>4 risks factors for nanoparticles </li></ul><ul><li>Form </li></ul><ul><li>Carbon nanotubes, C60 fullerenes … </li></ul><ul><li>Animal model in vivo </li></ul><ul><li>Human model in vitro </li></ul>Activation fibrosis Aortic endothelial cell apoptosis Vascular and cardiac toxicity Brain damage
  • 21. NANOTECHNOLOGY RISKS <ul><li>In human and public health  </li></ul><ul><li>4 risks factors for nanoparticles </li></ul><ul><li>Persistancy </li></ul><ul><li>In tissues </li></ul><ul><li>To immune system </li></ul>Inflammatory reaction Fibrosis Cancers
  • 22. NANOTECHNOLOGY RISKS <ul><li>In human and public health  </li></ul><ul><li>Pathogen effects on the lungs </li></ul><ul><li>Skin penetration and body distribution ? </li></ul><ul><li>« Free » nanoparticles </li></ul><ul><li>Alimentary chain ? </li></ul><ul><li>Environment ? </li></ul>Bioaccumulation et biopersistancy
  • 23. NANOTECHNOLOGY RISKS <ul><li>For the environment </li></ul><ul><li>Difficulties for measurement and control </li></ul><ul><li>Models : fullerenes … </li></ul><ul><li>Air, soil, surface water, underground water </li></ul><ul><li>Living organisms ( Bacteria, Fauna, Flora) </li></ul><ul><li>Decontamination potential </li></ul>Pollution risks ? OR Case by case studies Different properties
  • 24. NANOTECHNOLOGY RISKS <ul><li>For professionals </li></ul><ul><li>Scientifics </li></ul><ul><li>Laboratories </li></ul><ul><li>Toxicologics et ecotoxicologics properties </li></ul><ul><li>Data base recording </li></ul><ul><li>Once a year, CHS-CT </li></ul><ul><li>For industries </li></ul><ul><li>Entreprises, public organisms </li></ul><ul><li>All status confounded </li></ul><ul><li>CHS-CT </li></ul>
  • 25. RISK MANAGEMENT <ul><li>At european level, one example : NANOSAFE 1 </li></ul><ul><li>Control of productions </li></ul><ul><li>Safe use of nanomaterials </li></ul><ul><li>Evidency of lack of informations </li></ul><ul><li>Then NANOSAFE 2, in 2005 till 2009 </li></ul><ul><li>6 steps of risk management </li></ul>
  • 26. RISK MANAGEMENT <ul><li>At european level, NANOSAFE 2 </li></ul>
  • 27. RISK MANAGEMENT <ul><li>At european level, NANOSAFE 1 </li></ul><ul><li>Control of productions </li></ul><ul><li>Safe use of nanomaterials </li></ul><ul><li>Evidency of lack of informations </li></ul><ul><li>Then NANOSAFE 2, in 2004 till 2009 </li></ul><ul><li>6 steps of risk management </li></ul><ul><li>4 independant subprojects </li></ul>
  • 28. RISK MANAGEMENT <ul><li>At european level, NANOSAFE 2 </li></ul>SP1 : Detection and characterization techniques
  • 29. RISK MANAGEMENT <ul><li>At european level, NANOSAFE 2 </li></ul>SP2 : Health hazard assessment
  • 30. RISK MANAGEMENT <ul><li>At european level, NANOSAFE 2 </li></ul>SP3 : Development of secure industrial production systems and safe applications
  • 31. RISK MANAGEMENT <ul><li>At european level, NANOSAFE 2 </li></ul>SP4 : Societal and Environmental aspects
  • 32. RISK MANAGEMENT <ul><li>At european level, NANOSAFE 2 </li></ul>
  • 33. RISK MANAGEMENT <ul><li>Precautionary Principle </li></ul><ul><li>List nanoparticles </li></ul><ul><li>Produce new knowledges </li></ul><ul><li>Adopt safety measures </li></ul><ul><li>Protect the population and ecosystems </li></ul><ul><li>Lead a reglementary reflexion </li></ul>REACH
  • 34. CONCLUSIONS <ul><li>1 nanometer = 10 atoms </li></ul><ul><li>Exponential evolution </li></ul><ul><li>1188 « Nanoproducts » on PEN </li></ul><ul><li>High challenge for sanitary risk management and toxicological research </li></ul><ul><li>Lack of information </li></ul><ul><li>Amiante, OGM </li></ul><ul><li>Approach based on precaution </li></ul><ul><li>All in really close future !!! </li></ul>
  • 35. CONCLUSIONS <ul><li>Nanoproducts already for consumers !!! </li></ul>Thanks for your attention !!!

Related Documents